Requa’s Charcocaps activated charcoal
Data submitted "do not support the effectiveness of activated charcoal as a digestive aid ingredient for the relief of the symptoms of gastrointestinal distress," FDA says in a recent letter to the company. "Accordingly, activated charcoal cannot be reclassified to Category I based on these data." Requa had submitted a citizen petition requesting that activated charcoal be reclassified from Category III to Category I for relief of gastrointestinal distress ("The Pink Sheet" Nov. 4, 1991, T&G-11).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth